SLIT2 and breast carcinoma: Chang et al. showed that CAFs expressing the ligand Slit2 inhibited the tumorigenicity of breast cancer cells expressing the corresponding Robo1-receptor on their surface, thereby suggesting Slit2 as a potential effector of this tumor-inhibitory CAF-subtype [29].